Finalist

Rhythm Pharmaceuticals International Team

Summary of work

People living with rare genetic causes of obesity and their families have been left behind by the health system and society at large. For the first time in 2022, the International Team at Rhythm Pharmaceutical began to change that. Entering their second year in 2023, they faced bigger challenges than ever: advancing scientific and genetic understanding, limited disease awareness beyond ten global experts, disjointed referral and care pathways, huge societal stigma, and a growing internal team. The team was undaunted. Stories from patients and healthcare professionals left them safe in the knowledge that the first and only precision medicine would change the lives of patients. Moreover, it was apparent that even a diagnosis can change the direction of a life and absolve families of crippling blame and stigma. The success of increasing awareness and subsequent diagnosis meant the existing community could simply not handle the volume of new patients, so expanding the size and scale of those interested in this neglected field was a huge job. United in their purpose, collaborating with healthcare professionals and, most importantly, patients, by the close of 2023, this small team had transformed the lives of more patients and caregivers than had previously been imaginable.

Judges’ comments

Rhythm demonstrated its significant presence and high level of expertise within the rare disease market. The judges liked its focus on evolution and data dissemination, and revolution – growing the internal team and the diagnosis of more patients. Some fantastic achievements for such a small team and a great use of truly integrated omnichannel platforms.